The AKR1D1*36 (rs1872930) Allelic Variant Is Independently Associated With Clopidogrel Treatment Outcome

References

• Lenzi J, Fantini MP, Avaldi VM, et al. [Characteristics and outcomes of acute coronary syndrome in Italian-born patients and immigrants: a population-based observational study using health administrative data of the Emilia-Romagna Region]. G Ital Cardiol (Rome). 2017;18(9):650–659. doi:10.1714/2741.2794828845876
   PubMedGoogle Scholar
• Maupas E, Lipiecki J, Levy R, et al. Safety and efficacy outcomes of 3rd generation DES in an all-comer population of patients undergoing PCI: 12-month and 24-month results of the e-Biomatrix French registry. Catheter Cardiovasc Interv. 2017;90(6):890–897. doi:10.1002/ccd.2708128544186
   PubMed Web of Science ®Google Scholar
• Obeid S, Yousif N, Schelldorfer A, et al. Short-term outcome after left main interventions in patients presenting with acute coronary syndrome. J Invasive Cardiol. 2018;30(3):98–104.29493510
   PubMed Web of Science ®Google Scholar
• Stahli BE, Wischnewsky MB, Jakob P, et al. Predictive value of the age, creatinine, and ejection fraction (ACEF) score in patients with acute coronary syndromes. Int J Cardiol. 2018;270:7–13. doi:10.1016/j.ijcard.2018.05.13429885826
   PubMed Web of Science ®Google Scholar
• Xia J, Xu J, Li B, et al. Association between glycemic variability and major adverse cardiovascular and cerebrovascular events (MACCE) in patients with acute coronary syndrome during 30-day follow-up. Clin Chim Acta. 2017;466:162–166. doi:10.1016/j.cca.2017.01.02228111271
   PubMed Web of Science ®Google Scholar
• Claassens DMF, Vos GJA, Bergmeijer TO, et al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N Engl J Med. 2019. doi:10.1056/NEJMoa1907096
   Web of Science ®Google Scholar
• Rosano GMC, Seferovic P. 2017 ESC guidelines focus on dual antiplatelet therapy. Eur Heart J Cardiovasc Pharmacother. 2018;4(3):131–132. doi:10.1093/ehjcvp/pvy00730052849
   PubMed Web of Science ®Google Scholar
• Erlinge D, James S, Duvvuru S, et al. Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease. Thromb Haemost. 2014;111(5):943–950. doi:10.1160/TH13-09-076724402637
   PubMed Web of Science ®Google Scholar
• Cresci S, Depta JP, Lenzini PA, et al. Cytochrome p450 gene variants, race, and mortality among clopidogrel-treated patients after acute myocardial infarction. Circ Cardiovasc Gene. 2014;7(3):277–286. doi:10.1161/CIRCGENETICS.113.000303
   PubMed Web of Science ®Google Scholar
• Chaudhry AS, Thirumaran RK, Yasuda K, et al. Genetic variation in aldo-keto reductase 1D1 (AKR1D1) affects the expression and activity of multiple cytochrome P450s. Drug Metab Dispos. 2013;41(8):1538–1547. doi:10.1124/dmd.113.05167223704699
   PubMed Web of Science ®Google Scholar
• Tracy TS, Chaudhry AS, Prasad B, et al. Interindividual variability in cytochrome P450-mediated drug metabolism. Drug Metab Dispos. 2016;44(3):343–351. doi:10.1124/dmd.115.06790026681736
   PubMed Web of Science ®Google Scholar
• Chen M, Penning TM. 5beta-Reduced steroids and human Delta(4)-3-ketosteroid 5beta-reductase (AKR1D1). Steroids. 2014;83:17–26. doi:10.1016/j.steroids.2014.01.01324513054
   PubMed Web of Science ®Google Scholar
• The AKR1D1*36 (rs1872930) allelic variant is independently associated with Clopidogrel treatment outcome. DOI:10.6084/m9.figshare.7232978.v2 2019 https://figshare.com/articles/The_AKR1D1_36_rs1872930_allelic_variant_is_independently_associated_with_Clopidogrel_treatment_outcome_in_Acute_Coronary_Syndrome_patients/7232978 Accessed 102, 2019.
   Google Scholar
• Lang TA, Altman DG. Basic statistical reporting for articles published in biomedical journals: the “Statistical Analyses and Methods in the Published Literature” or the SAMPL Guidelines. Int J Nurs Stud. 2015;52(1):5–9. doi:10.1016/j.ijnurstu.2014.09.00625441757
   PubMed Web of Science ®Google Scholar
• Stark AE. Estimation of divergence from Hardy-Weinberg form. Twin Res Hum Genet. 2015;18(4):399–405. doi:10.1017/thg.2015.4126138075
   PubMed Web of Science ®Google Scholar
• Jakovski K, Nestorovska AK, Labacevski N, Dimovski AJ. Characterization of the most common CYP2C9 and CYP2C19 allelic variants in the population from the Republic of Macedonia. Pharmazie. 2013;68(11):893–898.24380239
   PubMed Web of Science ®Google Scholar
• Kapedanovska Nestorovska A, Jakovski K, Naumovska Z, et al. Distribution of the most common genetic variants associated with a variable drug response in the population of the Republic of Macedonia. Balkan J Med Genet. 2014;17(2):5–14. doi:10.2478/bjmg-2014-0069
   PubMed Web of Science ®Google Scholar
• Sherry ST, Ward MH, Kholodov M, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001;29(1):308–311. doi:10.1093/nar/29.1.30811125122
   PubMed Web of Science ®Google Scholar
• Mathur S, Sutton J. Personalized medicine could transform healthcare. Biomed Rep. 2017;7(1):3–5. doi:10.3892/br.2017.92228685051
   PubMed Web of Science ®Google Scholar
• Gladding P, Webster M, Zeng I, et al. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc Interv. 2008;1(6):620–627. doi:10.1016/j.jcin.2008.09.00819463375
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Trenk D, Schror K, et al. Response variability to P2Y12 receptor inhibitors: expectations and reality. JACC Cardiovasc Interv. 2013;6(11):1111–1128. doi:10.1016/j.jcin.2013.06.01124262612
   PubMed Web of Science ®Google Scholar
• Yang Y, Lewis JP, Hulot JS, Scott SA. The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19. Expert Opin Drug Metab Toxicol. 2015;11(10):1599–1617. doi:10.1517/17425255.2015.106875726173871
   PubMed Web of Science ®Google Scholar
• Cavallari LH, Lee CR, Beitelshees AL, et al. Multisite investigation of outcomes with implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention. JACC Cardiovasc Interv. 2018;11(2):181–191. doi:10.1016/j.jcin.2017.07.02229102571
   PubMed Web of Science ®Google Scholar
• Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363–375. doi:10.1056/NEJMoa080822719106083
   PubMed Web of Science ®Google Scholar
• Anderson CD, Biffi A, Greenberg SM, Rosand J. Personalized approaches to clopidogrel therapy: are we there yet? Stroke. 2010;41(12):2997–3002. doi:10.1161/STROKEAHA.110.59406921030701
   PubMed Web of Science ®Google Scholar
• Harmsze AM, van Werkum JW, Hackeng CM, et al. The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. Pharmacogenet Genomics. 2012;22(3):169–175. doi:10.1097/FPC.0b013e32834ff6e322228204
   PubMed Web of Science ®Google Scholar
• Huang B, Cui DJ, Ren Y, Han B, Yang DP, Zhao X. Effect of cytochrome P450 2C19*17 allelic variant on cardiovascular and cerebrovascular outcomes in clopidogrel-treated patients: A systematic review and meta-analysis. J Res Med Sci. 2017;22:109. doi:10.4103/jrms.JRMS_976_1629026425
   PubMed Web of Science ®Google Scholar
• Li Y, Tang HL, Hu YF, Xie HG. The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients. J Thromb Haemost. 2012;10(2):199–206. doi:10.1111/j.1538-7836.2011.04570.x22123356
   PubMed Web of Science ®Google Scholar
• Tangri N, Ferguson TW, Whitlock RH, et al. Long term health outcomes in patients with a history of myocardial infarction: A population based cohort study. PLoS One. 2017;12(7):e0180010. doi:10.1371/journal.pone.018001028700669
   PubMed Web of Science ®Google Scholar
• Mahmoud KD, Sanon S, Habermann EB, et al. Perioperative cardiovascular risk of prior coronary stent implantation among patients undergoing noncardiac surgery. J Am Coll Cardiol. 2016;67(9):1038–1049. doi:10.1016/j.jacc.2015.11.06326940923
   PubMed Web of Science ®Google Scholar